Showing 6661-6670 of 10001 results for "".
- MDRejuvena Launches Vivatia Skin Lightening Product Line in UShttps://practicaldermatology.com/news/mdrejuvena-launches-vivatia-skin-lightening-product-line-in-us/2458014/MDRejuvena, Inc., has launched the Vivatia skin lightening product line in the US. Vivatia incorporates a patented, proprietary foam technology that enhances the dispersion and absorption of active ingredients into the skin. Vivatia has been clinically studied and proven effective for hyperpigmen
- Omar A. Ibrahimi, MD, PhD, Wins ASDS Award for Outstanding Servicehttps://practicaldermatology.com/news/omar-a-ibrahimi-md-phd-wins-asds-award-for-outstanding-service/2458022/Omar A. Ibrahimi, MD, PhD, of Stamford, Connecticut, took home the 2017
- Dermavant Sciences Appoints Vince Ippolito as President and COOhttps://practicaldermatology.com/news/dermavant-sciences-appoints-vince-ippolito-as-president-and-coo/2458034/Dermavant Sciences, a biopharmaceutical company focused on developing therapies for dermatologic conditions, appointed Vince Ippolito as President and Chief Operating Officer. "I am extremely pleased to welcome Vince Ippolito
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C
- Lilly to Present New Data for Olumiant® and Taltz® at EADVhttps://practicaldermatology.com/news/lilly-to-present-new-data-for-olumiant-and-taltz-eadv/2458060/Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the develo
- Deion Sanders Named Brand Ambassador for Botox Cosmetichttps://practicaldermatology.com/news/deion-sanders-named-brand-ambassador-for-botox-cosmetic/2458062/NFL analyst and philanthropist Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, is the new brand ambassador for BOTOX® Cosmetic. Allergan also released two vide
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&
- RXI Completes Enrollment of Phase 2 Study of Samcyprone for Cutaneous Wartshttps://practicaldermatology.com/news/rxi-completes-enrollment-of-phase-2-study-of-samcyprone-for-cutaneous-warts/2458067/RXi Pharmaceuticals Corporation completed enrollment in its Phase 2 clinical trial, RXI-SCP-1502, with Samcyprone™for the clearance of cutaneous warts. Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopr
- AD Breakthrough? Medimetriks' MM36 Achieves Rapid Itch Relief, Safety in Phase 2 Studyhttps://practicaldermatology.com/news/ad-breakthrough-medimetriks-mm36-achieves-rapid-itch-relief-safety-in-phase-2-study/2458068/Medimetriks’ PDE4 inhibitor, MM36, appears to be safe, well-tolerated and provides rapid itch relief when applied twice daily to pediatric and adolescent atopic dermatitis (AD) patients, according to results of a Phase 2 study. The company ex